Stoke Therapeutics Inc Stock
Stoke Therapeutics Inc Stock
Heavy losses for Stoke Therapeutics Inc today as the stock fell by -€1.000 (-8.850%).
With 15 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 21 € there is a hugely positive potential of 98.11% for Stoke Therapeutics Inc compared to the current price of 10.6 €.
So far the community has only identified positive things for Stoke Therapeutics Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Stoke Therapeutics Inc in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Stoke Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | -8.850% | -3.636% | - | - | - | - | - |
| Personalis Inc | -5.570% | 10.315% | -1.146% | -39.192% | -37.788% | -93.246% | - |
| Immuron | -3.570% | 1.818% | 0.000% | 29.480% | 34.132% | -47.418% | - |
Comments
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target raised by analysts at Wedbush from $13.00 to $17.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for STOK provided by MarketBeat